Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) EBITDA (2016 - 2025)

Historic EBITDA for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to -$4.4 million.

  • Lisata Therapeutics' EBITDA rose 1727.89% to -$4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.1 million, marking a year-over-year increase of 1450.71%. This contributed to the annual value of -$22.4 million for FY2024, which is 1283.26% up from last year.
  • Per Lisata Therapeutics' latest filing, its EBITDA stood at -$4.4 million for Q3 2025, which was up 1727.89% from -$4.9 million recorded in Q2 2025.
  • Lisata Therapeutics' EBITDA's 5-year high stood at -$4.4 million during Q3 2025, with a 5-year trough of -$6.9 million in Q2 2023.
  • In the last 3 years, Lisata Therapeutics' EBITDA had a median value of -$5.8 million in 2025 and averaged -$5.7 million.
  • Within the past 5 years, the most significant YoY rise in Lisata Therapeutics' EBITDA was 1966.55% (2024), while the steepest drop was 355.06% (2024).
  • Lisata Therapeutics' EBITDA (Quarter) stood at -$6.0 million in 2023, then rose by 17.86% to -$4.9 million in 2024, then rose by 10.81% to -$4.4 million in 2025.
  • Its EBITDA stands at -$4.4 million for Q3 2025, versus -$4.9 million for Q2 2025 and -$5.8 million for Q1 2025.